Dr. Kenneth Shain, MD, PhD, is an Associate Member at Moffitt Cancer Center with a primary appointment in the Department of Malignant Hematology, and a secondary appointment in the Department of Chemical Biology and Molecular Medicine. In addition, he is the Co-Director of the Pentecost Myeloma Research Center, Scientific Director of the Moffitt Myeloma Working Group and Director of the ORIEN Multiple Myeloma Disease Interest Group. As a clinician-scientist he investigates the pathobiology of multiple myeloma (MM) and mechanisms of therapy resistance, including intrinsic mechanisms of resistance, mediated by bone marrow tumor microenvironment (TME), to identify novel targets and tools to improve the management of multiple myeloma (MM). On the clinical side he treats MM patients and directs MM clinical trials. Dr. Shain's research has three major focuses: (i) development and use of pharmacoproteomic tools to identify vulnerabilities of MM and to identify drivers of therapy resistance in the context of the TME; (ii) development and use of ex vivo tools informed by mathematical models for personalized management of MM; and (iii) development and use of tissue, molecular and clinical bio-repositories/databases centered around gene expression profiling, whole exome sequencing (WES) and RNA sequencing (RNAseq) of MM patient specimens, to identify predictive and prognostic molecular biomarkers, with the ultimate objective to address the critical need to identify tractable vulnerabilities to inform the development of targeted therapeutics with biomarkers facilitating truly personalized management in MM.